Drug
Nabiximols clinical trials
Also written Sativex and GW-1000-02.
- studies test it
- 61
- open now
- 1
- in phase 3
- 35
- first study started
- 2001
Keep track of what changes. Save the nabiximols studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Sativex
- 51
Development codes
Studies by the year they started
60 studies that test it; most in 2002 (9)
| Year | Studies |
|---|---|
| 2001 | 4 |
| 2002 | 9 |
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 13
- Phase 3
- 35
- Phase 4
- 1
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 45 · Other 16
Jazz Pharmaceuticals (35) · GW Pharmaceuticals Ltd (7) · Centre for Addiction and Mental Health (2) · McMaster University (1) · University of California, San Diego (1) · Hannover Medical School (1) · King's College London (1) · IRCCS Centro Neurolesi Bonino Pulejo (1)
Often tested with
Tested in the same studies.
GW-2000-02 (3) · Dronabinol (2) · Cannabidiol (2) · Cannabinol (1) · Methadone (1)
Studies
Open first, then newest update. How each study uses nabiximols is read from its arms, and is right about nine times in ten.
Testing it · 61
- Proof of Concept Trial of Cannabis Derivatives in Neuropathic PainRecruitingPhase 2VA Office of Research and DevelopmentNCT05351801Written as THC + CBD (Nabiximols)
- A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum DisordersWithdrawnPhase 2Michael, Levy M.D.,Ph.D.NCT05974293Written as Nabiximols
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisTerminatedPhase 3Jazz PharmaceuticalsNCT04984278Written as Nabiximols
- The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and CannabidiolActive, not recruitingPhase 1McMaster UniversityNCT05742724Written as Tetrahydrocannabinol-Cannabidiol Combination
- Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisTerminatedPhase 3Jazz PharmaceuticalsNCT04203498Written as Nabiximols
- The Effect of Cannabis in Pancreatic CancerWithdrawnPhase 2Jens Rikardt AndersenNCT03245658Written as THC and CBD Mixture
- Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisCompletedPhase 3Jazz PharmaceuticalsNCT04657666Written as Nabiximols
- Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple SclerosisCompletedPhase 3Jazz PharmaceuticalsNCT00702468Written as Sativex
- A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.CompletedPhase 3Jazz PharmaceuticalsNCT00711646Written as Sativex®
- A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)CompletedPhase 3Jazz PharmaceuticalsNCT00681538Written as Sativex®
- A Study of the Long-term Safety of Sativex UseCompletedPhase 3Jazz PharmaceuticalsNCT01606137Written as GW-1000-02
- Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related PainCompletedPhase 3Jazz PharmaceuticalsNCT00675948Written as Sativex
- A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple SclerosisCompletedPhase 3Jazz PharmaceuticalsNCT00678795Written as Sativex®
- A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.CompletedPhase 3Jazz PharmaceuticalsNCT00713323Written as Sativex®
- A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic PainCompletedPhase 3Jazz PharmaceuticalsNCT00713817Written as Sativex®
- A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple SclerosisCompletedPhase 3Jazz PharmaceuticalsNCT01599234Written as Sativex
- A Study of Sativex® for Pain Relief Due to Diabetic NeuropathyCompletedPhase 3Jazz PharmaceuticalsNCT00710424Written as Sativex
- A Study of Sativex® for Pain Relief in Patients With Advanced MalignancyCompletedPhase 3Jazz PharmaceuticalsNCT00674609Written as Sativex®
- A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With AllodyniaCompletedPhase 3Jazz PharmaceuticalsNCT00710554Written as Sativex
- A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.CompletedPhase 3Jazz PharmaceuticalsNCT00711880Written as Sativex®
See all 61 studies that test nabiximols →
Given in every arm · 1 — nabiximols is usual care beside what is tested
As the comparator · 3 — what is tested is compared with nabiximols
- Comparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult VolunteersCompletedPhase 1One World Cannabis Ltd.NCT03936907Written as Sativex
- 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy VolunteersCompletedPhase 1PhytoTech Therapeutics, Ltd.NCT03201835Written as Sativex
- Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol)CompletedPhase 1Hadassah Medical OrganizationNCT01893424Written as Sativex buccal spray
Codes
What other systems call nabiximols · ClinicalTrials.gg INT006460
- MeSH (NLM) C587251nabiximolsConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K4H93P747ONABIXIMOLSConfirmed FDA, NLM, Wikidata
- Wikidata Q891968nabiximolsConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71037NabiximolsOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C587251 | nabiximols | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K4H93P747O | NABIXIMOLS | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q891968 | nabiximols | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71037 | Nabiximols | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.